GlassScriptPhysician profile
Angela M Walling
NPI 1679508253
$108,423.17
in general payments reported to CMS, 2019-2025
27 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23K · 2022: $19K · 2023: $16K · 2024: $36K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $62K · Food and Beverage: $3,506 · Travel and Lodging: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $61,503.22 |
| Food and Beverage | $3,506.08 |
| Travel and Lodging | $1,206.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $98,225.60 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $6,211.29 | 2021-2022 | |
| Lilly USA, LLC | $717.19 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $708.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $606.44 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $464.48 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $244.33 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.66 | 2021-2025 | Jardiance, Combivent Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $157.23 | 2022-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $99.20 | 2021-2023 | Trintellix |
| Glaxosmithkline, LLC. | $77.26 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $69.13 | 2021-2025 | |
| Therapeuticsmd, INC. | $68.74 | 2021-2022 | |
| Exact Sciences Corporation | $67.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $43.14 | 2023-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $30.38 | 2022 | |
| Avion Pharmaceuticals | $24.51 | 2021-2022 | |
| Coopersurgical, INC. | $22.23 | 2025 | Paragard T 380a |
| Otsuka America Pharmaceutical, INC. | $21.30 | 2023 | Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $17.51 | 2022 | |
| Evofem Biosciences, INC. | $16.83 | 2021 | |
| Millicent US INC | $16.75 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.10 | 2021 | |
| Amarin Pharma, INC. | $15.16 | 2021 | |
| Exeltis, USA INC. | $14.35 | 2022 | |
| Currax Pharmaceuticals LLC | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Walling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.